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Dendritic cells (DCs) are widely con-
sidered as the most potent antigen-pre-
senting cells (APCs) in mammals and 
hence have been extensively harnessed for 
the development of anticancer vaccines.1 
In spite of such an intense wave of inves-
tigation, DC-based anticancer vaccines, 
which mainly rely on monocyte-derived 
DCs expanded ex vivo, have yielded low 
response rates so far, a finding that begs 
the question: “What is lacking in current 
DC-based vaccine formulations”?
Effective therapeutic vaccines must 
drive the development of high-avidity 
antigen-specific CD8+ T cells that display 
strong effector functions and long-term 
survival. In addition to signal 1 (provided 
by the peptide-MHC class I complex) 
and signal 2 (provided by co-stimulatory 
ligands), a third signal appears to be 
essential for CD8+ T cells to differentiate 
and acquire effector functions. Mescher 
and colleagues identified the biologically 
active form of interleukin-12 (IL-12p70) 
and Type I interferon (IFNα and IFNβ) 
as the critical cytokines that delivers sig-
nal 3 to resting naïve T cells.2 The signal 
delivered by these inflammatory cytokines 
enforces a genetic program that results in 
the coordinated expression of several genes 
involved in T-cell effector functions, self-
renewal, and homeostasis.3,4
Since data on the capacity of clinical 
DC preparations to produce IL-12p70 
were not available, we initiated a clinical 
trial to test the hypothesis that function-
ally mature IL-12p70-producing DCs 
would drive antigen-specific immune 
responses in patients with metastatic 
(stage IV) melanoma, and improve clini-
cal outcome.5 There were 2 major points 
to be considered in the design of this trial. 
First, what would be the most appropri-
ate clinical setting for testing of this 
vaccination strategy and second, what 
would be the optimal maturation signals 
needed to trigger IL-12p70 synthesis by 
DCs. We chose to study newly diagnosed 
melanoma patients with minimal yet 
measurable tumor burden and selected 3 
well-characterized gp100-derived HLA-
A*0201-restricted peptides as antigens.5 
A combination of CD40 ligand (CD40L, 
also known as CD154) and IFNγ was 
employed to manufacture functionally 
mature IL-12p70-producing DCs. Since 
no clinical grade CD40L material was 
available in 2006, good manufactur-
ing practice (GMP)-grade, cell-bound 
trimeric CD40L was produced in our 
laboratory in the form of human CD154 
expressed by K562 leukemia cells.
We treated 7 stage IV melanoma 
patients with autologous DCs pulsed with 
gp100-derived peptides and matured with 
CD40L and IFNγ. Although these indi-
viduals were not pre-screened for IL-12p70 
production, we observed that monocyte-
derived DCs from 4 of the 7 patients 
exhibited a selective defect (less than 
1 ng/106cells/24h) in the synthesis of this 
cytokine upon exposure to CD40L/IFNγ 
in vitro. Further analyses revealed defects 
in the transcription of the IL-12 monomer 
IL-12p35, resulting in impaired IL-12p70 
production. This defect was subsequently 
confirmed in additional melanoma 
patients, using age- and gender-matched 
healthy subjects as controls. Importantly, 
we found that the addition of Toll-like 
receptor 3 (TLR3) and TLR8 agonists, i.e., 
polyinosinic: polycytidylic acid (polyI:C) 
and R848, respectively, together with 
CD40L/IFNγ could correct the IL-12p70 
production defect in monocyte-derived 
DCs from melanoma patients.
Such a specific impairment in IL-12p35 
transcription allowed us to study the effects 
of administering DCs that secrete low or 
high amounts of IL-12p70, providing a 
unique opportunity to define the role of 
IL-12p70 in immunological and clinical 
outcomes. Immunological responses to all 
3 gp100-derived peptides were observed in 
6 of 7 patients. Interestingly, the magnitude 
of these immune responses, as assessed by 
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HLA-A2/gp100 peptide tetramer analy-
sis of peripheral blood mononuclear cells 
(PBMCs) collected in the course of vac-
cination, did not correlate with IL-12p70 
production. Conversely, a key finding of 
our study was that the production levels 
of IL-12p70 by DCs correlated with dis-
ease outcomes, as monitored in terms of 
time to progression (Fig. 1). Patients whose 
DCs produced IL12p70 in amounts equal 
or superior to those of healthy subjects had 
objective radiographic responses that lasted 
≥ 11.5 mo. To date, 2 of these 3 patients 
remain alive and well. In contrast, patients 
bearing DCs that produced low IL-12p70 
levels exhibited rapid disease progression.
We also examined the cytokine pro-
files of vaccine-induced CD8+ T cells 
upon antigenic stimulation, in order 
to assess Type 1 (Tc1) or Type 2 (Tc2) 
polarization. A clear dichotomy in IFNγ/
IL-13 and IFNγ/IL-5 ratios was observed 
between clinical responders and non-
responders, with responders displaying 
a Tc1 bias (i.e., high IFNγ/IL-13 and 
IFNγ/IL-5 ratios) and non-responders 
exhibit Tc2-skewed responses (i.e., low 
IFNγ/IL-13 and IFNγ/IL-5 ratios). 
Thus, Tc1 immunity correlated with 
objective clinical responses while patients 
exhibiting a Tc2 bias exhibited rapid dis-
ease progression. This proof-of-concept 
clinical study indicates that the paracrine 
production of IL-12p70 by DCs in the 
course of T-cell priming plays a critical 
role in skewing immune responses toward 
a Tc1 profile, which influences disease 
outcome in melanoma patients with min-
imal disease burden.
In support of the capacity of IL-12p70 
to program a therapeutic Tc1 CD8+ T-cell 
response, Mescher and colleagues have 
recently demonstrated that this cytokine, 
and not type I IFN, renders activated 
CD8+ T cells less susceptible to inhibi-
tion by the programmed cell death 1 
(PDCD1, best known as PD1), leading to 
improved disease control in murine tumor 
models.6 In a separate study, human cir-
culating myeloid CD1c+ DCs were iden-
tified as robust producers of IL-12p70 
upon CD40L/IFNγ maturation and as 
driver of IFNγ-secreting antigen-specific 
CD8+ T cells.7 These findings suggest 
that myeloid CD1c+ DCs may consti-
tute an optimal population of APCs for 
the development of anti-cancer vaccines 
based on in situ antigen targeting. In sum, 
accumulating evidence supports further 
studies of IL-12p70 as an adjuvant for 
anticancer vaccine in clinical trials. In 
our opinion, DCs may constitute the best 
source to provide IL-12p70 to CD4+ and 
CD8+ T cells in a temporally and spatially 
appropriate manner during antigen-pre-
sentation. The challenge is now to identify 
the best means to regulate the paracrine 
production of IL-12p70 by DCs in order 
to elicit therapeutic Tc1 immunity in can-
cer patients.
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Figure 1. IL-12p70-producing dendritic cell (DC)-based vaccines elicit Tc1 immunity leading to clinical 
responses in melanoma patients. (A and B) autologous monocyte-derived dendritic cells (DCs) were 
activated with CD40 ligand (CD40L) and interferon γ (IFNγ), resulting in the generation of function-
ally mature IL-12p70-producing DCs for administration to cancer patients. The amounts of IL-12p70 
secreted by these cells varied dramatically among patients, and we chose to discriminate between 
high (> 1 ng/106cells/24h) (A) and low (< 1 ng/106cells/24hrs) (B) producers. The DCs producing low 
levels of IL-12p70 exhibited impaired IL12p35 transcription, resulting in the preferential secretion of 
IL-12p40 instead of IL-12p70. The levels of IL-12p70 secreted by DCs did not correlate with the magni-
tude of vaccine-induced gp100-specific CD8+ T-cell responses. however, patients immunized with 
DCs secreting high IL-12p70 levels developed a Tc1-biased immune response characterized by robust 
production of IFNγ over IL-5 and IL-13. In contrast, the administration of DCs producing low amounts 
of IL-12p70 drove the development of Tc2-skewed responses. a correlation was observed between 
the amounts of IL-12p70 produced by DCs, the development of Tc1 immunity and clinical responses.
